reboxetine has been researched along with 3,4-methylenedioxyamphetamine in 1 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (3,4-methylenedioxyamphetamine) | Trials (3,4-methylenedioxyamphetamine) | Recent Studies (post-2010) (3,4-methylenedioxyamphetamine) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 4,806 | 77 | 1,373 |
| Protein | Taxonomy | reboxetine (IC50) | 3,4-methylenedioxyamphetamine (IC50) |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.2314 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.7129 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.996 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.6486 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brenneisen, R; Grouzmann, E; Hoener, MC; Huwyler, J; Hysek, CM; Ineichen, M; Liechti, ME; Simmler, LD | 1 |
1 trial(s) available for reboxetine and 3,4-methylenedioxyamphetamine
| Article | Year |
|---|---|
The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.
Topics: 3,4-Methylenedioxyamphetamine; Adrenergic Uptake Inhibitors; Adult; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Hallucinogens; Heart Rate; Humans; Male; Morpholines; N-Methyl-3,4-methylenedioxyamphetamine; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Reboxetine; Young Adult | 2011 |